Neurochem Fibrillex misses endpoint
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Neurochem's amyloid A amyloidosis agent Fibrillex fails to meet its primary endpoint in a Phase II/III trial, the firm says April 18. Preliminary results from the two-year, 183-patient study found there were 13.4% more patients on Fibrillex than placebo who remained stable or improved (p=0.06). The primary endpoint required a 20% absolute difference in the number of stabilized/improved patients versus placebo (p<0.01). Neurochem, which previously projected a 2005 NDA submission, says it remains committed to Fibrillex and will discuss its complete Phase II/III findings with FDA. Fibrillex was accepted into FDA's continuous marketing application Pilot 2 program by the cardio-renal division in July 2004 (1Pharmaceutical Approvals Monthly December 2004, p. 17)...
You may also be interested in...
FDA Extends Continuous Marketing Application Pilot 2 Deadline Again
FDA extends continuous marketing application Pilot 2 deadline again. At least eight CDER divisions have chosen INDs for the fast-track pilot program, with eight remaining. Applications will be accepted until Dec. 31
Spring Launch For Germany’s Digital Strategy
Interested parties have been consulted, workshop findings noted and online surveys completed; the drafting of Germany’s digital health strategy is now underway.
Paradox Of China Biotech And What Lies Ahead In 2023
The hard going could get even tougher as a funding crunch continues for China’s biotech sector, which is being hit by a paradox that could see more pain ahead, leading investors to take the pulse of the sector as the Year of the Rabbit starts.